← All drugs
Drug · FAERS side-effect profile with label screen

Metoprolol Succinate side effects: what 86,126 FDA adverse event reports show

Metoprolol Succinate · Metoprolol Tartrate · 1,174 reaction terms · 329,152 drug–reaction co-reports · data 2026-09-14
Share: X Facebook Reddit Email

Drug class

Beta-adrenergic blocker

FDA label, Indications wording

Brand names

Metoprolol Tartrate

openFDA label

Who reports

86,126 reports · 63% serious · 7,928 with death outcome · 56% female

openFDA FAERS counts, all years, deduplication not applied

Used for

Metoprolol tartrate tablet is a beta-adrenergic blocker indicated for the treatment of: • Hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) • Angina Pectoris.

FDA label, Indications and Usage

What it is

Metoprolol tartrate tablets, USP contain metoprolol tartrate, USP a selective beta 1 -adrenoreceptor blocking agent. Metoprolol tartrate, USP is (±)-1-(Isopropylamino)-3-[p-(2-methoxyethyl) ph.

FDA label, Description section

Boxed warning

None in the current label

How to read this page. FAERS is a spontaneous-reporting system: counts are not incidence rates and a signal is not proof of causation. Each reaction below is run through an automated screen — is the term in the FDA label (known), in the indications (the disease being treated), an administrative/coding term, or none of these (unlabeled)? That screen is mechanical text matching, not a causality assessment. The 30 hand-written Bradford Hill assessments are on the causality assessment page. Not medical advice.

Causality screen of the 40 strongest signals

Labeled adverse reaction 1Labeled (related wording) 2Likely indication confounding 5Reporting / coding artifact 1Not in label — unassessed 31
What the badges mean

Strongest disproportionality signals

Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only (and, for the 300 most-reported drugs, adjusted for age band), and flags pairs whose reports are unusually skewed by sex or come mostly from consumers. Each row also shows the PRR against the other drugs of the same FDA class, which removes most confounding by the condition being treated, and a calibrated p-value: on validation, known non-causes average an ROR of about 2, so significance is judged against that empirical null (✓ = p < 0.05 after calibration). 1,134 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.

Show:
ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Suspected suicide37520.7
18.6–23.0ROR 20.8 · calibrated p 0.002 ✓
19.1 EB05 17.5 · IC025 +4.1
3/3 methods agree
Likely indication confounding
shares a disease stem with the indications wording
serious n=375 · 100% clinicianno trial arm names this drug
Brash syndrome10520.3
16.7–24.8ROR 20.4 · calibrated p 0.002 ✓
18.8 EB05 15.9 · IC025 +3.8
3/3 methods agree
Not in label — unassessedserious n=105 · 100% clinicianno trial arm names this drug
Chronic kidney disease-mineral and bone disorder7919.2
15.3–24.2ROR 19.2 · calibrated p 0.003 ✓
17.8 EB05 14.7 · IC025 +3.6
3/3 methods agree
Not in label — unassessedserious n=79no trial arm names this drug
Nephrogenic anaemia27415.1
13.4–17.1ROR 15.1 · calibrated p 0.007 ✓
14.2 EB05 12.9 · IC025 +3.6
3/3 methods agree
Not in label — unassessedserious n=274no trial arm names this drug
Hyperparathyroidism secondary14614.8
12.6–17.5ROR 14.9 · calibrated p 0.008 ✓
14.0 EB05 12.2 · IC025 +3.5
3/3 methods agree
Not in label — unassessedserious n=146no trial arm names this drug
Essential hypertension13012.8
10.7–15.3ROR 12.8 · calibrated p 0.014 ✓
12.1 EB05 10.4 · IC025 +3.3
3/3 methods agree
Likely indication confounding
shares a disease stem with the indications wording
serious n=119no trial arm names this drug
Obstructive sleep apnoea syndrome5710.3
7.9–13.4ROR 10.3 · calibrated p 0.032 ✓
9.6 EB05 7.6 · IC025 +2.8
3/3 methods agree
Not in label — unassessedserious n=55 · ♀ 100% (drug 56%)no trial arm names this drug
Aortic valve stenosis7210.2
8.0–12.9ROR 10.2 · calibrated p 0.033 ✓
9.5 EB05 7.7 · IC025 +2.8
3/3 methods agree
Not in label — unassessedserious n=72 · ♀ 100% (drug 56%) · 100% clinicianno trial arm names this drug
Rebound acid hypersecretion1139.3
7.7–11.2ROR 9.3 · calibrated p 0.043 ✓
8.8 EB05 7.5 · IC025 +2.8
3/3 methods agree
Not in label — unassessedserious n=112no trial arm names this drug
Infusion site discharge608.8
6.8–11.4ROR 8.8 · calibrated p 0.053
8.2 EB05 6.5 · IC025 +2.6
3/3 methods agree
Not in label — unassessedserious n=45 · ♀ 100% (drug 56%) · 100% consumerno trial arm names this drug
Haemorrhagic anaemia1558.7
7.4–10.2ROR 8.7 · calibrated p 0.052
8.3 EB05 7.3 · IC025 +2.8
3/3 methods agree
Not in label — unassessedserious n=155no trial arm names this drug
Blood pressure inadequately controlled2028.4
7.3–9.6ROR 8.4 · calibrated p 0.059
8.0 EB05 7.1 · IC025 +2.8
3/3 methods agree
Likely indication confounding
shares a disease stem with the indications wording
serious n=115no trial arm names this drug
Eyelid pain648.3
6.4–10.6ROR 8.3 · calibrated p 0.064
7.7 EB05 6.2 · IC025 +2.5
3/3 methods agree
Not in label — unassessed♀ 100% (drug 56%) · 100% consumerno trial arm names this drug
Tachyarrhythmia797.9
6.3–9.9ROR 7.9 · calibrated p 0.072
7.4 EB05 6.1 · IC025 +2.5
3/3 methods agree
Not in label — unassessedserious n=78 · 100% clinicianno trial arm names this drug
Aortic arteriosclerosis797.7
6.1–9.6ROR 7.7 · calibrated p 0.079
7.2 EB05 5.9 · IC025 +2.5
3/3 methods agree
Not in label — unassessedserious n=79no trial arm names this drug
Coronary artery disease8527.0
6.5–7.4ROR 7.0 · calibrated p 0.098
6.8 EB05 6.4 · IC025 +2.6
3/3 methods agree
Labeled adverse reaction
exact term
serious PRR 6.3no trial arm names this drug
End stage renal disease5096.9
6.3–7.5ROR 6.9 · calibrated p 0.102
6.7 EB05 6.2 · IC025 +2.6
3/3 methods agree
Not in label — unassessedserious PRR 6.2no trial arm names this drug
Diastolic dysfunction856.8
5.5–8.5ROR 6.8 · calibrated p 0.110
6.5 EB05 5.4 · IC025 +2.3
3/3 methods agree
Likely indication confounding
shares a disease stem with the indications wording
serious n=80no trial arm names this drug
Arteriosclerosis coronary artery1796.7
5.8–7.8ROR 6.8 · calibrated p 0.111
6.5 EB05 5.7 · IC025 +2.5
3/3 methods agree
Not in label — unassessedserious n=177no trial arm names this drug
Diverticulum intestinal1186.7
5.6–8.1ROR 6.8 · calibrated p 0.112
6.4 EB05 5.5 · IC025 +2.4
3/3 methods agree
Not in label — unassessedserious n=116no trial arm names this drug
Anti-neutrophil cytoplasmic antibody positive vasculitis656.6
5.2–8.5ROR 6.6 · calibrated p 0.120
6.2 EB05 5.0 · IC025 +2.2
3/3 methods agree
Not in label — unassessedserious n=65 · ♀ 100% (drug 56%) · 100% clinicianno trial arm names this drug
Infusion site haemorrhage856.5
5.3–8.1ROR 6.5 · calibrated p 0.124
6.2 EB05 5.2 · IC025 +2.3
3/3 methods agree
Not in label — unassessedserious n=49 · 100% consumerno trial arm names this drug
Blood loss anaemia586.5
5.0–8.4ROR 6.5 · calibrated p 0.129
6.0 EB05 4.8 · IC025 +2.2
3/3 methods agree
Not in label — unassessedserious n=58 · ♀ 0% (drug 56%)no trial arm names this drug
Hepatic cyst886.5
5.2–8.0ROR 6.5 · calibrated p 0.127
6.1 EB05 5.1 · IC025 +2.3
3/3 methods agree
Not in label — unassessedserious n=87 · ♀ 100% (drug 56%)no trial arm names this drug
Product administration interrupted1976.4
5.5–7.4ROR 6.4 · calibrated p 0.128
6.2 EB05 5.5 · IC025 +2.4
3/3 methods agree
Reporting / coding artifactserious n=170no trial arm names this drug
Atrial flutter2056.4
5.5–7.3ROR 6.4 · calibrated p 0.129
6.1 EB05 5.5 · IC025 +2.4
3/3 methods agree
Not in label — unassessedserious PRR 5.5no trial arm names this drug
Chronic gastritis576.3
4.9–8.2ROR 6.3 · calibrated p 0.136
5.9 EB05 4.7 · IC025 +2.1
3/3 methods agree
Not in label — unassessedserious n=56 · ♀ 100% (drug 56%) · 100% consumerno trial arm names this drug
Coronary artery bypass1466.3
5.3–7.4ROR 6.3 · calibrated p 0.135
6.0 EB05 5.3 · IC025 +2.3
3/3 methods agree
Not in label — unassessedserious n=145 · ♀ 33% (drug 56%)no trial arm names this drug
Ischaemic cardiomyopathy735.8
4.6–7.4ROR 5.9 · calibrated p 0.165
5.5 EB05 4.6 · IC025 +2.1
3/3 methods agree
Likely indication confounding
shares a disease stem with the indications wording
serious n=73 · ♀ 0% (drug 56%)no trial arm names this drug
Body height decreased2535.8
5.1–6.6ROR 5.8 · calibrated p 0.164
5.6 EB05 5.1 · IC025 +2.3
3/3 methods agree
Not in label — unassessedserious n=157 · 74% consumerno trial arm names this drug
Aortic stenosis815.8
4.6–7.2ROR 5.8 · calibrated p 0.170
5.5 EB05 4.6 · IC025 +2.1
3/3 methods agree
Not in label — unassessedserious n=80no trial arm names this drug
Seasonal allergy3215.6
5.0–6.3ROR 5.7 · calibrated p 0.176
5.5 EB05 5.0 · IC025 +2.3
3/3 methods agree
Not in label — unassessedserious n=146 · 75% consumerno trial arm names this drug
Coronary artery occlusion3015.4
4.8–6.1ROR 5.4 · calibrated p 0.194
5.3 EB05 4.8 · IC025 +2.2
3/3 methods agree
Not in label — unassessedserious PRR 4.9no trial arm names this drug
Ventricular extrasystoles2265.4
4.7–6.1ROR 5.4 · calibrated p 0.198
5.2 EB05 4.7 · IC025 +2.2
3/3 methods agree
Not in label — unassessedage-adj. PRR 4.3 · serious PRR 4.7no trial arm names this drug
Atrial fibrillation2,1185.4
5.2–5.6ROR 5.5 · calibrated p 0.188
5.3 EB05 5.1 · IC025 +2.3
3/3 methods agree
Not in label — unassessedage-adj. PRR 3.6 · serious PRR 4.8no trial arm names this drug
Pre-existing condition improved1365.3
4.5–6.3ROR 5.3 · calibrated p 0.203
5.2 EB05 4.5 · IC025 +2.1
3/3 methods agree
Not in label — unassessedserious n=78no trial arm names this drug
Hiatus hernia2785.3
4.7–6.0ROR 5.3 · calibrated p 0.204
5.2 EB05 4.7 · IC025 +2.2
3/3 methods agree
Not in label — unassessedserious PRR 5.1no trial arm names this drug
Tricuspid valve incompetence1645.1
4.4–6.0ROR 5.1 · calibrated p 0.222
5.0 EB05 4.4 · IC025 +2.1
3/3 methods agree
Not in label — unassessedserious PRR 4.7no trial arm names this drug

Clinical concept groups

MedDRA splits one clinical problem across several terms (e.g. "neutropenia", "neutrophil count decreased", "agranulocytosis"), which dilutes term-level signals. These rows count reports with any term in a concept group (an exact union, not a sum), compared with all other drugs. Groups are hand-built and listed in the methods.

ConceptReportsPRR 95% CIReading
Arrhythmia / qt3,1033.93.8–4.1signal
Heart failure2,5063.43.3–3.6signal
Myocardial infarction2,8113.43.3–3.5signal
Gi bleeding1,9012.52.4–2.7signal
Kidney injury4,0952.22.1–2.3signal
Fall / fracture3,2792.12.0–2.2signal
Anaemia2,4192.01.9–2.0raised
Hyponatraemia6291.91.8–2.1raised
Stroke1,8281.81.7–1.9raised
Serious infection5,5771.81.7–1.8raised
Thrombocytopenia1,3751.51.4–1.6raised
Venous thromboembolism1,3271.51.4–1.6raised
Hyperglycaemia / diabetes2,0531.41.4–1.5raised
Rhabdomyolysis / myopathy4711.41.3–1.5raised
Depression1,5791.41.3–1.4raised
Hypoglycaemia4931.31.1–1.4raised

Trial evidence (ClinicalTrials.gov)

ClinicalTrials.gov returned results-bearing trials mentioning Metoprolol Succinate only as a background or rescue medication (NCT00000620, NCT00716079); no trial listing it as the tested intervention was cached, so no trial cross-check is shown.

Most frequently reported reactions

By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.

ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Diarrhoea (diarrhea)5,2902.0
2.0–2.1ROR 2.1 · calibrated p 0.985
2.0 EB05 2.0 · IC025 +1.0Labeled adverse reaction
exact term
age-adj. PRR 1.6 · serious PRR 1.8no trial arm names this drug
Nausea5,0221.6
1.5–1.6ROR 1.6 · calibrated p 0.698
1.5 EB05 1.5 · IC025 +0.6Labeled adverse reaction
exact term
age-adj. PRR 1.4 · serious PRR 1.7no trial arm names this drug
Dyspnoea (shortness of breath)4,9302.1
2.1–2.2ROR 2.2 · calibrated p 0.952
2.1 EB05 2.1 · IC025 +1.0
3/3 methods agree
Labeled adverse reaction
exact term
age-adj. PRR 1.7 · serious PRR 2.0no trial arm names this drug
Drug ineffective (drug did not work)4,2710.8
0.8–0.8ROR 0.8 · calibrated p 0.171
0.8 EB05 0.8 · IC025 -0.4
PRR-only: not supported by EBGM or IC
Reporting / coding artifactage-adj. PRR 0.9 · serious PRR 0.9no trial arm names this drug
Off label use (used outside approved label)4,2271.2
1.2–1.2ROR 1.2 · calibrated p 0.437
1.2 EB05 1.2 · IC025 +0.2Reporting / coding artifactage-adj. PRR 1.1 · serious PRR 1.1no trial arm names this drug
Dizziness4,2152.1
2.0–2.1ROR 2.1 · calibrated p 0.990
2.1 EB05 2.0 · IC025 +1.0
3/3 methods agree
Labeled adverse reaction
exact term
age-adj. PRR 1.8 · serious PRR 2.1no trial arm names this drug
Headache3,8611.5
1.5–1.6ROR 1.5 · calibrated p 0.659
1.5 EB05 1.5 · IC025 +0.5Labeled adverse reaction
exact term
age-adj. PRR 1.5 · serious PRR 1.5no trial arm names this drug
Death3,5401.0
1.0–1.0ROR 1.0 · calibrated p 0.306
1.0 EB05 1.0 · IC025 -0.1
PRR-only: not supported by EBGM or IC
Outcome field, not a reactionage-adj. PRR 0.9 · serious PRR 0.9no trial arm names this drug
Asthenia (weakness)3,2672.1
2.1–2.2ROR 2.2 · calibrated p 0.968
2.1 EB05 2.1 · IC025 +1.0
3/3 methods agree
Not in label — unassessedage-adj. PRR 1.7 · serious PRR 2.0no trial arm names this drug
Pain3,2101.3
1.2–1.3ROR 1.3 · calibrated p 0.495
1.3 EB05 1.2 · IC025 +0.3Labeled adverse reaction
exact term
age-adj. PRR 1.5 · serious PRR 1.2no trial arm names this drug
Fall3,1042.3
2.2–2.4ROR 2.3 · calibrated p 0.888
2.3 EB05 2.2 · IC025 +1.1
3/3 methods agree
Not in label — unassessedage-adj. PRR 1.7 · serious PRR 2.1no trial arm names this drug
Pneumonia (lung infection)2,6172.0
1.9–2.1ROR 2.0 · calibrated p 0.949
2.0 EB05 1.9 · IC025 +0.9Not in label — unassessedage-adj. PRR 1.6 · serious PRR 1.8no trial arm names this drug
Cough2,5622.2
2.2–2.3ROR 2.3 · calibrated p 0.914
2.2 EB05 2.2 · IC025 +1.1
3/3 methods agree
Not in label — unassessedage-adj. PRR 1.8 · serious PRR 2.0no trial arm names this drug
Malaise (feeling unwell)2,4741.4
1.3–1.4ROR 1.4 · calibrated p 0.563
1.4 EB05 1.3 · IC025 +0.4Not in label — unassessedage-adj. PRR 1.2 · serious PRR 1.3no trial arm names this drug

Unlabeled candidate signals

These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.

Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.

Common questions

What are the most reported side effects of Metoprolol Succinate?

In FDA FAERS, the most frequently co-reported reaction terms for Metoprolol Succinate are fatigue, diarrhoea, nausea, dyspnoea, dizziness, headache. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.

Does Metoprolol Succinate have an FDA boxed warning?

No. The FDA label retrieved for Metoprolol Succinate has no boxed warning; see the label's Warnings and Precautions for the recognised risks.

Do FAERS signals prove that Metoprolol Succinate causes these side effects?

No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.

Sources & methods

Page generated 2026-10-14. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.